Femasys (FEMY) Stock Price, News & Analysis

Company Overview

Femasys Inc. is a women’s health company focused on developing and commercializing minimally invasive technologies for reproductive health and fertility care. The company’s products are designed to provide non-surgical or less invasive alternatives for contraception, diagnostic procedures and treatments involving the female reproductive system.

Femasys’ lead product candidate is FemBloc, an investigational, non-surgical permanent birth-control system intended to prevent pregnancy by blocking the fallopian tubes. The company is also developing FemCath, a transcervical catheter designed to facilitate access to the fallopian tubes for diagnostic and therapeutic procedures. Its product portfolio has also included FemVue, a system used in certain fertility-related procedures to evaluate fallopian-tube patency.

Founded in 2004 and based in Atlanta, Georgia, Femasys primarily operates in the United States and is advancing its technologies through clinical development, regulatory activities and commercialization efforts. The company is led by founder and Chief Executive Officer Kathy Lee-Sepsick.

Key Stats

• Today's Range: $2.51 to $2.64
• 50-Day Range: $2.16 to $3.91
• 52-Week Range: $2.02 to $22.20
• Volume: 35,027 shs
• Average Volume: 152,341 shs
• Market Capitalization: $21.70 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $50.00
• Consensus Rating: Moderate Buy

Femasys Stock Analysis - MarketRank™

Femasys scored higher than 67% of companies evaluated by MarketBeat, and ranked 238th out of 897 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.9 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Femasys has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 3 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Femasys has a consensus price target of $50.00, representing about 1,830.5% upside from its current price of $2.59.

Amount of Analyst Coverage

Femasys has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Femasys is -0.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Femasys is -0.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Femasys has a P/B Ratio of 1.29. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

7.68% of the float of Femasys has been sold short.

Short Interest Ratio / Days to Cover

Femasys has a short interest ratio ("days to cover") of 0.16, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Femasys has recently increased by 36.34%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Femasys does not currently pay a dividend.

Dividend Growth

Femasys does not have a long track record of dividend growth.

News and Social Media

• Score: 2.5 / 5
• News Sentiment: 0.05

News Sentiment

Femasys has a news sentiment score of 0.05. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.56 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Femasys this week, compared to 2 articles on an average week.

Search Interest

Only 1 people have searched for FEMY on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

MarketBeat Follows

1 people have added Femasys to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 4.6 / 5
• Insider Trading: Acquiring Shares

Cluster Insider Buying

4 insiders have purchased shares of Femasys in the last three months. Multiple insiders buying is a strong bullish signal.

Net Insider Buying

Over the last three months, insiders have purchased a net $124,000.00 in company stock, which represents 0.5713% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, Femasys insiders have bought more of their company's stock than they have sold. Specifically, they have bought $124,000.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

7.75% of the stock of Femasys is held by insiders.

Percentage Held by Institutions

65.27% of the stock of Femasys is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/14/2026
• Today: 9/19/2026
• Next Earnings (Estimated): 11/17/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Healthcare Equipment & Supplies
• Sub-Industry: Healthcare Equipment
• Current Symbol: NASDAQ:FEMY
• CIK: 1339005
• Web: www.femasys.com
• Phone: 770-500-3910
• Fax: N/A
• Employees: 54
• Year Founded: 2004

Price Target and Rating

• Average Price Target for Femasys: $50.00
• High Price Target: $130.00
• Low Price Target: $10.00
• Potential Upside/Downside: +1,830.5%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): ($3.53)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$18.63 million
• Net Margins: -534.36%
• Pretax Margin: -511.61%
• Return on Equity: -225.97%
• Return on Assets: -74.68%

Debt

• Debt-to-Equity Ratio: 0.89
• Current Ratio: 2.14
• Quick Ratio: 0.55

Sales & Book Value

• Annual Sales: $2.29 million
• Price / Sales: 9.48
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.01 per share
• Price / Book: 1.29

Miscellaneous

• Outstanding Shares: 8,380,000
• Free Float: 7,726,000
• Market Cap: $21.70 million
• Optionable: Not Optionable
• Beta: -2.07